{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:58:13Z","timestamp":1783022293333,"version":"3.54.6"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.bmcl.2023.129290","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T12:15:10Z","timestamp":1681820110000},"page":"129290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Discovery and development of benzene sulfonamide derivatives as anti-hepatic fibrosis agents"],"prefix":"10.1016","volume":"88","author":[{"given":"Weiping","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juxian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2023.129290_b0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmcl.2023.129290_b0010","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2019.03.004","article-title":"Global liver disease burdens and research trends: Analysis from a Chinese perspective","volume":"71","author":"Jia","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmcl.2023.129290_b0015","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev.pharmtox.45.120403.095906","article-title":"Hepatic fibrosis: molecular mechanisms and drug targets","volume":"45","author":"Lotersztajn","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.bmcl.2023.129290_b0020","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.bmcl.2023.129290_b0025","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJMra1504367","article-title":"Treatment of Patients with Cirrhosis","volume":"375","author":"Ge","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2023.129290_b0030","first-page":"397","article-title":"Mechanisms of hepatic stellate cell activation. Nature Reviews","volume":"14","author":"Takuma","year":"2017","journal-title":"Gastroenterology & Hepatology"},{"key":"10.1016\/j.bmcl.2023.129290_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399403005684","article-title":"Molecular basis of hepatic fibrosis","volume":"5","author":"Hui","year":"2003","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.bmcl.2023.129290_b0040","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.3748\/wjg.v20.i23.7260","article-title":"Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update","volume":"20","author":"Elpek","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.bmcl.2023.129290_b0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","article-title":"Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues","volume":"65","author":"Maurizio","year":"2019","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.bmcl.2023.129290_b0050","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrgastro.2010.97","article-title":"Evolving challenges in hepatic fibrosis","volume":"7","author":"Friedman","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.bmcl.2023.129290_b0055","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040875","article-title":"Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives","volume":"9","author":"Roehlen","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bmcl.2023.129290_b0060","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3390\/cells9040875","article-title":"Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives","volume":"9","author":"Natascha","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bmcl.2023.129290_b0065","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.tox.2008.06.013","article-title":"Hepatic fibrosis \u2013 overview","volume":"254","author":"Friedman","year":"2008","journal-title":"Toxicology"},{"key":"10.1016\/j.bmcl.2023.129290_b0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0168-8278(00)80413-4","article-title":"New aspects of hepatic fibrosis","volume":"32","author":"Brenner","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmcl.2023.129290_b0075","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1056\/NEJM199306243282508","article-title":"The Cellular Basis of Hepatic Fibrosis \u2013 Mechanisms and Treatment Strategies","volume":"328","author":"Friedman","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2023.129290_b0080","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.addr.2017.05.007","article-title":"Hepatic stellate cells as key target in liver fibrosis","volume":"121","author":"Takaaki","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bmcl.2023.129290_b0085","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1369\/0022155415627681","article-title":"TGF-\u03b2\/SMAD Pathway and Its Regulation in Hepatic Fibrosis","volume":"64","author":"Xu","year":"2016","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.bmcl.2023.129290_b0090","first-page":"189","article-title":"Cell therapy in chronic liver disease","volume":"32","author":"Nicolas","year":"2016","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.bmcl.2023.129290_b0095","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1111\/j.1440-1746.2006.04584.x","article-title":"Hepatic stellate cells and the reversal of fibrosis","volume":"21","author":"Kisseleva","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.bmcl.2023.129290_b0100","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1002\/hep.20974","article-title":"Reversal of hepatic fibrosis \u2013 fact or fantasy?","volume":"43","author":"Friedman","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.bmcl.2023.129290_b0105","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","article-title":"Hepatic fibrosis: Concept to treatment","volume":"62","author":"Christian","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmcl.2023.129290_b0110","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.32285","article-title":"Hepatic fibrosis 2022: Unmet needs and a blueprint for the future","volume":"75","author":"Friedman","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.bmcl.2023.129290_b0115","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26061545","article-title":"Novel IMB16-4 Compound Loaded into Silica Nanoparticles Exhibits Enhanced Oral Bioavailability and Increased Anti-Liver Fibrosis In Vitro","volume":"26","author":"Niu","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2023.129290_b0120","doi-asserted-by":"crossref","DOI":"10.3390\/ph15010085","article-title":"New IMB16-4 Nanoparticles Improved Oral Bioavailability and Enhanced Anti-Hepatic Fibrosis on Rats","volume":"15","author":"Niu","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bmcl.2023.129290_b0125","first-page":"27(12)","article-title":"Established Liposome-Coated IMB16-4 Polymeric Nanoparticles (LNPs) for Increasing Cellular Uptake and Anti-Fibrotic Effects In Vitro","author":"Niu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2023.129290_b0130","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1021\/ja00086a022","article-title":"Mechanistic Aspects of the Reaction of Anionic Iron(0)-Olefin Complexes with Organic Halides. Detection and Characterization of Paramagnetic Organometallic Intermediates","volume":"116","author":"Hill","year":"1994","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2023.129290_b0135","article-title":"Design, synthesis and bioactivity study of N-salicyloyl tryptamine derivatives as multifunctional agents for the treatment of neuroinflammation","volume":"193","author":"Xiaohong","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129290_b0140","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.matbio.2017.12.012","article-title":"Matrix metalloproteinases and liver fibrosis (translational aspects)","volume":"68\u201369","author":"Roeb","year":"2018","journal-title":"Matrix Biol"},{"key":"10.1016\/j.bmcl.2023.129290_b0145","first-page":"169","article-title":"Establishment and application of a high-throughput drug screening model based on COL1A1 promoter for anti-liver fibrosis","volume":"50","author":"Zhao","year":"2015","journal-title":"Yao Xue Xue Bao"},{"key":"10.1016\/j.bmcl.2023.129290_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116438","article-title":"Discovery of 1,8-naphthalidine derivatives as potent anti-hepatic fibrosis agents via repressing PI3K\/AKT\/Smad and JAK2\/STAT3 pathways","volume":"49","author":"Lu","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2023.129290_b0155","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/bph.13766","article-title":"The anti-hepatic fibrosis effects of dihydrotanshinone I are mediated by disrupting the yes-associated protein and transcriptional enhancer factor D2 complex and stimulating autophagy","volume":"174","author":"Ge","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmcl.2023.129290_b0160","article-title":"Discovery and development of palmatine analogues as anti-NASH agents by activating farnesoid X receptor (FXR)","volume":"245","author":"Na","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129290_b0165","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bph.14873","article-title":"Costunolide represses hepatic fibrosis through WW domain-containing protein 2-mediated Notch3 degradation","volume":"177","author":"Ge","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmcl.2023.129290_b0170","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2023.129290_b0175","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2020.07.028","article-title":"Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis","volume":"74","author":"Kj\u00e6rgaard","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmcl.2023.129290_b0180","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cbi.2009.07.015","article-title":"(-)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFRbeta and IGF-1R","volume":"182","author":"Yasuda","year":"2009","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.bmcl.2023.129290_b0185","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/aps.2014.155","article-title":"The anti-fibrotic effects of epigallocatechin-3-gallate in bile duct-ligated cholestatic rats and human hepatic stellate LX-2 cells are mediated by the PI3K\/Akt\/Smad pathway","volume":"36","author":"Yu","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.bmcl.2023.129290_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113111","article-title":"Epigallocatechin-3-gallate inhibits osteopontin expression and prevents experimentally induced hepatic fibrosis","volume":"151","author":"George","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmcl.2023.129290_b0195","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.tox.2010.04.014","article-title":"Epigallocatechin-3-gallate (EGCG) reduces liver inflammation, oxidative stress and fibrosis in carbon tetrachloride (CCl4)-induced liver injury in mice","volume":"273","author":"Tipoe","year":"2010","journal-title":"Toxicology"},{"key":"10.1016\/j.bmcl.2023.129290_b0200","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/BF02934504","article-title":"Molecular mechanisms of hepatic fibrosis and principles of therapy","volume":"32","author":"Friedman","year":"1997","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.bmcl.2023.129290_b0205","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1756-3305-3-60","article-title":"Hepatic stellate cells and parasite-induced liver fibrosis","volume":"3","author":"Anthony","year":"2010","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.bmcl.2023.129290_b0210","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/hep.510240333","article-title":"Expression of intracellular adhesion molecule 1 by activated hepatic stellate cells","volume":"24","author":"Hellerbrand","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.bmcl.2023.129290_b0215","unstructured":"Fluorine in Medicinal Chemistry and Chemical Biology. Edited by ed. I. Ojima. 2009: Wiley- Blackwell."},{"key":"10.1016\/j.bmcl.2023.129290_b0220","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1124\/pr.119.018440","article-title":"Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution","volume":"72","author":"Bharadwaj","year":"2020","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bmcl.2023.129290_b0225","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.2741\/3886","article-title":"JAK-STAT signaling in hepatic fibrosis","volume":"16","author":"Mair","year":"2011","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.bmcl.2023.129290_b0230","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19082299","article-title":"Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment","volume":"19","author":"Kasembeli","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2023.129290_b0235","article-title":"The Role of JAK\/STAT Pathway in Fibrotic Diseases: Molecular and Cellular Mechanisms","volume":"13","author":"Liu","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.bmcl.2023.129290_b0240","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1242\/dmm.012062","article-title":"Diverse functions of matrix metalloproteinases during fibrosis","volume":"7","author":"Giannandrea","year":"2014","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.bmcl.2023.129290_b0245","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2045-3701-1-14","article-title":"Tissue inhibitor of metalloproteinase 1 (TIMP-1) deficiency exacerbates carbon tetrachloride-induced liver injury and fibrosis in mice: involvement of hepatocyte STAT3 in TIMP-1 production","volume":"1","author":"Wang","year":"2011","journal-title":"Cell Biosci"},{"key":"10.1016\/j.bmcl.2023.129290_b0250","first-page":"2237","article-title":"Stat3 signaling activation crosslinking of TGF-\u03b21 in hepatic stellate cell exacerbates liver injury and fibrosis","volume":"1842","author":"Xu","year":"2014","journal-title":"BBA"},{"key":"10.1016\/j.bmcl.2023.129290_b0255","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41467-017-01236-6","article-title":"Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis","volume":"8","author":"Chakraborty","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2023.129290_b0260","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X23001683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X23001683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:47:52Z","timestamp":1760773672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X23001683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":52,"alternative-id":["S0960894X23001683"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129290","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and development of benzene sulfonamide derivatives as anti-hepatic fibrosis agents","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"129290"}}